Asthma & COPD Market Overall Study Report 2021-2028 | AstraZeneca, Novartis AG, GlaxoSmithKline plc, Merck & Co., Verona Pharma plc,

Asthma is a lung disease that affects millions of people worldwide. Breathing problems, chest pain, coughing, and wheezing are also possible symptoms.

The global asthma and COPD market is expected to account around US$ 30,710.2 Mn in terms of value in 2020 and is expected to reach over US$ 42,608 Mn by the end of 2027.

Global Asthma and COPD Market: Drivers

Rising incidences of asthma is expected to drive growth of the global asthma and COPD market during the forecast period. For instance, according to The Global Asthma Report 2018, around 300 million people have asthma globally, and the number is expected to reach 100 million by 2025.

To Get more Business Statergies Request for Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/4002

Global Asthma and COPD Market: Restraints

Drugs losing patent protection is expected to hamper growth of the global asthma and COPD market over the forecast period. For instance, AstraZeneca’s Daliresp (roflumilast) indicated for patients with severe COPD lost patent protection in January 2020.

Key Takeaways:

The global asthma and COPD market was accounted around US$ 29,386.8 Mn in 2019 and is forecast to reach a value over US$ 42,608.1 Mn by 2027 at a CAGR around 4.8% between 2020 and 2027. Major factor driving growth of global asthma and COPD market during the forecast period include high prevalence of respiratory diseases, and product launches

Combination Therapies held a significant position in the global asthma and COPD market in 2019, accounting for 57.0% share in terms of value, followed by Bronchodilators and Anti-Inflammatories, respectively. However, product releases in the combination therapies segment is expected to drive growth of the global asthma and COPD market during the forecast period.

Market Trends:

Rising investment towards development of inhalation products is expected to drive growth of the global asthma and COPD market. For instance, in July 2020, CF PharmTech, Inc. raised US$ 50 million in Series F financing to accelerate the commercialization of its inhalation products for the treatment of respiratory diseases.

Furthermore, growing R&D of new dry powder inhalation solutions is also expected to aid in growth of the global asthma and COPD market. For instance, in June 2020, researchers from University of Szeged, Hungary, developed carrier-based dry powder inhalation system, which is an interactive physical blend of a surface-modified carrier and a spray-dried drug with suitable shape and size for pulmonary application.

To Get Research PDF Brochure Here @ https://www.coherentmarketinsights.com/insight/request-pdf/4002

Global Asthma and COPD Market: Competitive Landscape

Key players in the global asthma and COPD market such as, Novartis AG, AstraZeneca, Merck & Co., GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Verona Pharma plc, Boehringer Ingelheim GmbH and GlaxoSmithKline plc.

Global Asthma and COPD Market: Key Developments

Key players in the global asthma and COPD market are concentrating on the acceptance and sale of new products due to extend their product range. For instance, Regeneron Pharmaceuticals, Inc. obtained the U.S. Food and Drug Administration (FDA) clearance for a 300 mg single-dose pre-filled pen for Dupixent (dupilumab) for use in some patients with atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP) for at-home administration in June 2020.

Key players in the global asthma and COPD market are concentrating on R&D of new therapies due to extend their product range. For instance, in May 2020, Verona Pharma plc, a clinical-stage biopharmaceutical company, the US Food and Drug Administration (FDA) provided written feedback in response to its End-of-Phase 2 briefing kit for nebulized ensifentrine as a COPD maintenance therapy.

Segmentation

• By Drug Type
o Bronchodilators
 Short Acting Bronchodilators
 Long Acting Bronchodilators
 Anticholinergics

o Anti-Inflammatories
 Inhaled Corticosteroids
 Anti-Leukotriene
 Monoclonal Antibodies
o Combination Therapies

• By Disease Type
o Asthma
o COPD
• By Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o Drug Stores

• By Region
o North America
o Latin America
o Europe
o Asia Pacific
o Middle East
o Africa

To Direct Purchase this Research Report – https://www.coherentmarketinsights.com/insight/buy-now/4002

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.